Why Fortis, Apollo, Max and Yatharth Hospital Stocks Rally Up to 5%

Government’s Proposed Margin Caps Boost Hospital Stocks Amid Regulatory Changes

Shares of major hospital chains surged as investors reacted positively to potential regulatory changes aimed at capping trade margins on non-scheduled cancer drugs.

Market Reaction to Regulatory News

The BSE Hospitals index rose by 1.5%, outperforming the broader BSE Sensex, which increased by 0.32%. This rally in hospital stocks is a stark contrast to the index’s recent performance, which had seen a decline of 12% over the past two weeks. The downturn was largely attributed to concerns raised by the Supreme Court regarding the disparity between the price-to-retailer (PTR) and maximum retail price (MRP) of essential medicines, particularly cancer drugs.

Details of the Proposed Margin Cap

According to reports, the National Pharmaceutical Pricing Authority (NPPA) has tentatively approved a proposal to limit trade margins for non-scheduled anti-cancer drugs to 30% of their MRP. This regulation is expected to encompass around 110 non-scheduled cancer medications, including both branded and generic options. The NPPA estimates that this move could lead to a reduction in maximum retail prices by 20% to 70%, potentially saving patients approximately ₹2,500 crore annually.

Implications for Hospital Profitability

ICICI Securities has noted that while the new regulation is likely to impact retailer margins more significantly, it could also affect hospital consumables, which account for about 35% of overall hospital bills. The average EBITDA margin for hospitals stands at 30-35%. The brokerage anticipates a potential EBITDA margin impact of 2-4% for hospitals, although further clarity is needed as the matter remains under judicial review.

Broader Market Context

The proposed changes come at a time when the healthcare sector is under scrutiny for pricing practices, particularly concerning essential medicines. The anti-cancer drugs market, valued at approximately ₹12,500 crore, has been criticized for its high trade mark-ups, which can reach up to 700%. The government’s intervention aims to enhance affordability and accessibility for patients, which could lead to a more favorable public perception of healthcare providers.

Key Highlights

• Hospital stocks, including Fortis and Apollo, rallied up to 5% following news of proposed margin caps.
• The BSE Hospitals index rose by 1.5%, contrasting with a 12% decline over the past two weeks.
• The NPPA plans to cap trade margins on non-scheduled cancer drugs at 30% of MRP.
• Expected savings for patients could reach ₹2,500 crore annually due to reduced drug prices.
• ICICI Securities anticipates a 2-4% impact on hospital EBITDA margins from the new regulations.

Investor Note: The proposed regulatory changes could enhance the affordability of cancer treatments, potentially benefiting hospital operators in the long run. However, investors should remain cautious about the immediate impacts on margins and monitor further developments as the situation evolves.